Type 3 macular neovascularization (MNV) is a subtype of neovascular age-related macular degeneration accounting for 10-20% of cases, notable for high rates of bilateral involvement and risk of profound vision loss, particularly if undertreated. Early and proactive therapy is crucial to prevent progression and preserve vision.
Faricimab offers potential advantages in this setting. Eyes with type 3 MNV often show thin choroid, reticular pseudodrusen, and high GA risk, reflecting compromised choroidal perfusion. While anti-vascular endothelial growth factor (VEGF) agents suppress neovascularization, prolonged VEGF blockade may impair choriocapillaris health. Ang-2 inhibition, by promoting Tie2 activation and vascular stability, may protect choriocapillaris and reduce widespread retinal edema and hemorrhages observed in type 3 MNV.
Finally, while treat-and-extend is widely used in practice, existing trials (TENAYA, LUCERNE) applied broader extension intervals than typically used clinically. In type 3 MNV, where undertreatment carries severe consequences, a more stringent faricimab-based treat-and-extend regimen with 2-week interval adjustments warrants investigation.

Start Date23 Sep 2025

Sponsor / Collaborator

Kim'S Eye Hospital

NCT07088445

/ Not yet recruitingNot ApplicableIIT

Therapeutic Prospects of Faricimab Injection for Patients Affected by Neovascular Age-Related Macular Degeneration

Neovascular Age-Related Macular Degeneration (nAMD) is one of the main causes of irreversible vision loss in the elderly, characterized by neovascularization and vascular leakage in the macular area, ultimately leading to damage to retinal structure and visual impairment. At present, anti vascular endothelial growth factor (VEGF) therapy is the main approach for treating nAMD, including VEGF inhibitors such as Aflibercept and Conbercept. However, some patients show decreased treatment tolerance or efficacy after long-term use of these drugs . Faricimab, a bispecific antibody that targets both VEGF and angiopoietin-2 (Ang-2), is expected to provide a new treatment option for patients resistant to existing VEGF therapies due to its unique dual mechanism of action The aim of this study is to explore the treatment response rate and prognosis of farnesyl monoclonal antibody in patients with refractory nAMD, including visual improvement and imaging changes, in order to provide more scientific treatment decision-making basis for clinical practice. At the same time, to determine its efficacy and safety in actual clinical treatment, in order to provide more flexible and personalized treatment options for nAMD patients, reduce their treatment burden, improve treatment compliance and quality of life.

Start Date01 Sep 2025

Sponsor / Collaborator

Chongqing Medical University /The First Affiliated Hospital/

ChiCTR2500106303

/ Not yet recruitingPhase 4IIT

A prospective study to evaluate the alterations of early macular microcirculation following intravitreal injection of faricimab for macular edema secondary to branch retinal vein occlusion

Start Date01 Sep 2025

Sponsor / Collaborator

The Second Affiliated Hospital of Chongqing Medical University

[+1]

100 Clinical Results associated with Faricimab

100 Translational Medicine associated with Faricimab

100 Patents (Medical) associated with Faricimab

377

Literatures (Medical) associated with Faricimab

31 Dec 2025·JOURNAL OF MEDICAL ECONOMICS

Cost-effectiveness analysis of bispecific antibody faricimab for treatment of neovascular age-related macular degeneration and diabetic macular edema in Japan

Article

Author: Igarashi, Ataru ; Sakashita, Naotaka ; Shoji, Ayako ; Higashi, Kentaro ; Tsujimura, Jun ; Ohno, Shinya ; Yanagi, Yasuo

OBJECTIVE:

To assess the cost-effectiveness of faricimab vs. other anti-vascular endothelial growth factor (anti-VEGF) drugs for treatment of neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME) in Japan, while considering societal burden associated with treatment.

METHODS:

A Markov model for cost-effectiveness analysis of anti-VEGF treatment in patients with nAMD and DME was applied based on cost and utility value data from Japan. Faricimab administered through a treat-and-extend (T&E) regimen was compared with ranibizumab administered pro re nata (PRN) and T&E, aflibercept T&E, brolucizumab T&E, and best supportive care (BSC). Further to treatment costs (public payer perspective), the societal burden (societal perspective), including costs of travel, informal care, and productivity, was assessed.

RESULTS:

In treatment of nAMD, lifetime quality-adjusted life years (QALYs) gained were highest with faricimab (faricimab T&E: 6.92, ranibizumab PRN: 6.88, ranibizumab T&E: 6.91, aflibercept T&E: 6.89, brolucizumab T&E: 6.89, BSC: 5.99). From the public payer perspective, the lifetime total cost for faricimab T&E was lower than those for ranibizumab (PRN, T&E) and brolucizumab (T&E), comparable to aflibercept T&E, and higher than BSC (incremental costs: 158,385 and 6,475,511 JPY, respectively). As a result, faricimab was cost-effective or dominant in the treatment of nAMD, excluding BSC. From the societal perspective, faricimab was dominant against all comparators in nAMD. In treatment of DME, QALYs gained were highest with faricimab (faricimab T&E: 8.51, ranibizumab PRN: 8.17, aflibercept PRN: 8.36, ranibizumab T&E: 8.13, BSC: 5.16). From both the public payer and societal perspectives, faricimab was dominant against all comparators in DME.

CONCLUSIONS:

When societal burdens were considered, faricimab was dominant in both nAMD and DME against all comparators, suggesting that the extended dosing interval associated with faricimab treatment may alleviate societal burdens and consequently improve patient outcomes.

31 Dec 2025·JOURNAL OF MEDICAL ECONOMICS

Cost-minimisation analysis of anti-VEGF therapies in neovascular age-related macular degeneration and diabetic macular oedema in Switzerland

Article

Author: Quist, S.W. ; Maamari, S. ; Boer, M. ; Ambresin, Aude ; Barthelmes, D.

OBJECTIVE:

This study compares the direct healthcare costs of anti-VEGF therapies, including treat-and-extend (T&E) and other durable regimens, for unilateral neovascular age-related macular degeneration (nAMD) and diabetic macular oedema (DMO) in Switzerland.

METHODS:

An adapted cost-minimisation model estimated healthcare costs over two years for aflibercept 2 mg, aflibercept 8 mg, faricimab, ranibizumab, and ranibizumab biosimilars using clinical trial injection frequencies. Break-even analyses identified the medication prices and injection frequencies required for higher-cost therapies to achieve cost parity with the least expensive options. A one-way sensitivity analysis (OWSA) assessed key drivers of cost outcomes.

RESULTS:

Aflibercept 8 mg was estimated to be associated with the lowest treatment costs for both indications (CHF 11,814 for nAMD; CHF 11,242 for DMO). Faricimab (CHF 13,737) and aflibercept 2 mg (CHF 15,243) followed in nAMD and DMO. Ranibizumab and its biosimilars incurred the highest costs: for nAMD, biosimilars ranged from CHF 16,243 to CHF 17,497 and the reference product reached CHF 18,424; for DMO, biosimilars ranged from CHF 18,187 to CHF 19,596, with the reference product at CHF 20,637. Break-even analyses for nAMD showed that prices would need to drop by -22% (faricimab, CHF 644) to -64% (ranibizumab reference, CHF 218) relative to aflibercept 8 mg. For DMO, reductions ranged from -42% (aflibercept 2 mg, CHF 493) to -81% (ranibizumab reference, CHF 114). The OWSA highlighted medication price and injection frequency as primary cost drivers.

CONCLUSIONS:

This study estimated that the potentially minimized injection frequency of aflibercept 8 mg in a clinical trial regimen may result in the lowest treatment costs for nAMD and DMO, followed by faricimab and aflibercept 2 mg, respectively.

01 Dec 2025·AMERICAN JOURNAL OF OPHTHALMOLOGY

Clinical Efficacy of Switching to Faricimab in Treatment Resistant Neovascular Age-Related Macular Degeneration: Systematic Review and Meta-analysis

Review

Author: Zhang, Charles ; Yannuzzi, Nicolas A ; Albini, Thomas A ; Leung, Nicholas ; Zhu, Daniel ; Lai, Daniel A ; Aboukasm, Georges

TOPIC:

Faricimab in the treatment of treatment-resistant neovascular age-related macular degeneration (nAMD).

CLINICAL RELEVANCE:

While many studies on faricimab in treatment-resistant eyes have reported improvements in retinal thickness (RT), the impact on visual acuity (VA) remains inconsistent. Additionally, variability in dosing protocols-with some studies utilizing loading interval for the first 3 injections while others continuing at the prior injection interval-introduces further uncertainty regarding the optimal treatment strategy. Understanding these differences is essential for guiding clinical decision-making and maximizing patient outcomes.

METHODS:

This systematic review and meta-analysis followed PRISMA guidelines and was registered in PROSPERO (CRD420251000088). A systematic search of PubMed, Embase, and Scopus (February 3, 2025) identified studies evaluating the effects of switching to faricimab in treatment-resistant nAMD. Inclusion criteria required patients to have received ≥3 prior anti-VEGF injections and ≥3 faricimab injections, with reported outcomes on RT, VA, fluid status, or injection intervals. Outcomes were measured following completion of loading dose and at last follow up, ranging from 3 months to 1.5 years. Studies were assessed for bias using ROBINS-I and NIH Quality Assessment tool and assessed for certainty of evidence using GRADE. Meta-analyses were conducted using mean differences, odds ratio, and random-effects models.

RESULTS:

Fourteen studies (926 eyes) met inclusion criteria. Switching to faricimab significantly reduced RT by 46.67 µm (95% CI: 35.91-57.42, I² = 0%, 721 eyes). Eyes that followed a loading interval were found to have greater reduction in RT than those that did not (I² = 74.1%, 640 eyes). The odds of achieving a dry macula increased 4.35-fold (95% CI: 2.95-6.42, I² = 64%, 379 eyes). Eyes with baseline VA <65 ETDRS letters showed a gain of 3.16 letters (95% CI: 0.80-5.52, I² = 0%, 439 eyes). Injection intervals were extended by 1.56 weeks (95% CI: 0.71-2.40, I² = 86%, 591 eyes). Using GRADE, 4 outcomes were graded as either very low (VA, dryness, and treatment interval) or low (RT).

CONCLUSION:

Switching to faricimab in treatment-resistant nAMD eyes significantly improved RT with no change in VA. This effect was greater with a loading interval protocol. Overall, there was an extension of injection intervals. Further prospective studies are needed to optimize dosing strategies and assess long-term efficacy.

282

News (Medical) associated with Faricimab

24 Sep 2025

·www.biopharmadive.com

Pharma’s next generation of antibodies takes a ‘more is better’ approach

The pharmaceutical industrys first multispecificantibody hit the market more than a decade ago. Now, the medicines are seeing a surge of interest as drugmakers and investors embrace the more-is-better approach for cancer or autoimmune diseases.These drugs,which include bispecifics and other multi-pronged approaches, builds on the therapeutic power of monoclonal antibodies by targeting two or more sites instead of one.The first bispecific therapy hit the market when the Food and Drug Administration cleared Amgens Blincyto in 2014. Since then, more than a dozen others have followed. Behind them in development are several tri-specific and higher-order multispecific antibodies, or msAbs.This newer generation of drugs has attracted industry interest due to promising clinical results and potentially improved safety profiles and pharmacokinetics, according to a report from Back Bay Life Science Advisors. The field has already generated two blockbusters: Genentechs Hemlibra, a hemophilia treatment, and Vabysmo, used to treat eye diseases. But more are expected to reach that billion-dollar threshold, said Peter Bak, a managing director at Back Bay and one of the reports authors.While all of the approved msAbs aside from Hemlibra and Vabysmo are cancer treatments, theres been a sizable shift in the pipeline toward autoimmune disease, thanks in part to the encouraging, albeit early findings seen with cell therapies.msABs' growing market potential250msAB candidates in clinical trials, 24 of which are in late-stage registrational studies.14msABs approved by the FDA (as of August 2025), including eight that have been approved since 2023.7msAB drugs in oncology on track to become blockbusters by 2030.Back Bay Life Science AdvisorsLupus is an area where there's been some interesting data generated by a couple academic groups, and now a lot of companies are rethinking their strategy, said Bak.Some believe that T cell engagers, which draw immune defenders to cancer cells, can also be used to tame the wayward B-cells that drive autoimmune disease. The hope is that these drugs will produce similar results to CAR-T, but at a lower cost, giving them a potential market advantage. In some cases, msAbs could treat patients who didnt respond to these other treatments, Bak said.In an area like systemic lupus erythematosus where there's not much activity, and there is pretty big unmet need, one could see it being used as a first line biologic, he added. Its going to be very indication specific.Investment influxThe potentially lucrative opportunity has drawn a flurry of investments. In the first half of 2025, immunology and inflammation msAb companies outraised their cancer-focused counterparts by $269 million, according to the report.Nearly 250 msAb candidates are now in trials, including 24 late-stage drugs, and dealmaking has accelerated. And transactions involving these drugs have been on par with deals for antibody drug conjugates (180 vs. 192 deals, respectively), another popular approach,for about the last five years, according to the report.Several companies are testing msAbs for autoimmune conditions. Roches Lunsumio, a bispecific targeting CD20 and CD3 and already approved for lymphoma, recently finished an early-stage trial in lupus, Bak noted.Amgen is testing Blincyto, its anti-CD19 x anti-CD3 bispecific T cell engager in phase 2 for both lupus with nephritis and refractory rheumatoid arthritis. Meanwhile, Cullinan Therapeutics bispecific T-cell engager,CLN-978, is in phase 1 trials for lupus and rheumatoid arthritis. Initial data from Cullinans trials are expected in the first half of 2026.The other asset that people are looking at thats in late-stage development is MoonLake [Immunotherapeutics] bispecific against two forms of IL-17, Bak said.Primary endpoint results for Moonlakes phase 3 program for hidradenitis suppurativa, a chronic autoimmune skin condition, are expected this month. If all goes as planned the company could file for approval in mid-2026.While interest in autoimmune research has accelerated, oncology indications are still garnering attention, including the bispecific and potential Keytruda rival, ivonescimab, which was developed by China-based Akeso and licensed to Summit Therapeutics. Companies are also exploring msAbs in neurology, neurodegenerative diseases and solid tumors.But there are manufacturing and other challenges to overcome. These drugs will also need to prove their worth compared to other ascending drugmaking strategies, such as radiopharmaceuticals,protein degradersand cell therapies.In hematology/oncology its already there. Its very much a commercial market where people are trying to optimize the dosing profiles and how its being delivered to patients, Bak said.Elsewhere, in areas such as autoimmune conditions,its very much a race to market right now, he added. '

Drug ApprovalPhase 2Phase 3ImmunotherapyPhase 1

22 Sep 2025

·www.globenewswire.com

XOMA Royalty Declares Quarterly Preferred Stock Dividends

EMERYVILLE, Calif., Sept. 22, 2025 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation (Nasdaq: XOMA) today announced its Board of Directors has authorized the following cash dividends to holders of XOMA Royalty’s Series A and Series B Cumulative Preferred Stock: Holders of the 8.625% Series A Cumulative Perpetual Preferred Stock (Nasdaq: XOMAP) shall receive a cash dividend equal to $0.53906 per share. Holders of depositary shares, each representing 1/1000 of a share of XOMA Royalty’s 8.375% Series B Cumulative Perpetual Preferred Stock (Nasdaq: XOMAO), shall receive a cash dividend equal to $0.52344 per depositary share. The preferred dividends will be paid on or about October 15, 2025, to respective holders of record at the close of business on October 3, 2025. About XOMA Royalty CorporationXOMA Royalty is a biotechnology royalty aggregator playing a distinctive role in helping biotech companies achieve their goal of improving human health. XOMA Royalty acquires the potential future economics associated with pre-commercial and commercial therapeutic candidates that have been licensed to pharmaceutical or biotechnology companies. When XOMA Royalty acquires the future economics, the sellers receive non-dilutive, non-recourse funding they can use to advance their internal drug candidate(s) or for general corporate purposes. XOMA Royalty has an extensive and growing portfolio of assets (asset defined as the right to receive potential future economics associated with the advancement of an underlying therapeutic candidate). For more information about XOMA Royalty and its portfolio, please visit www.xoma.com or follow XOMA Royalty Corporation on LinkedIn. EXPLANATORY NOTE: Any references to “portfolio” in this press release refer strictly to milestone and/or royalty rights associated with a basket of drug products in development. Any references to “assets” in this press release refer strictly to milestone and/or royalty rights associated with individual drug products in development. As of the date of this press release, the commercial assets in XOMA Royalty’s milestone and royalty portfolio are VABYSMO® (faricimab-svoa), OJEMDA™ (tovorafenib), MIPLYFFA™ (arimoclomol), XACIATO™ (clindamycin phosphate) vaginal gel 2%, IXINITY® [coagulation factor IX (recombinant)], and DSUVIA® (sufentanil sublingual tablet). All other assets in the milestone and royalty portfolio are investigational compounds. Efficacy and safety have not been established. There is no guarantee that any of the investigational compounds will become commercially available. Investor Contact Juliane Snowden XOMA Royalty Corporation +1-646-438-9754 juilane.snowden@xoma.comXOMA Royalty Media ContactKathy VincentKV Consulting & Managementkathy@kathyvincent.com

18 Sep 2025

·www.prnewswire.com

Innovent's Partner Ollin Announces Clinical Updates on IBI324 (OLN324, VEGF/ANG-2)

SAN FRANCISCO and SUZHOU, China, Sept. 18, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures, and commercializes high-quality medicines for the treatment of oncology, autoimmune, cardiovascular and metabolic, ophthalmology and other major disease areas, today announced that the company's partner Ollin reported a clinical update on IBI324 (Ollin R&D code: OLN324). IBI324 (OLN324) is a higher potency, higher molar dose VEGF/Ang2 bispecific antibody in Phase 1b clinical development for patients with either wet (neovascular) age-related macular degeneration (wAMD) or diabetic macular edema (DME), the leading causes of vision loss in older and working-aged people, respectively. Ollin has completed enrollment of over 150 patients with wAMD or DME in the JADE study, a randomized, U.S.-based, Phase 1b proof-of-concept clinical trial designed to evaluate OLN324 versus faricimab for potential areas of anatomic and durability differentiation. Topline results from the study are expected in the first quarter of 2026. Building on the proven backbone efficacy of anti-VEGF, OLN324's substantially higher anti-Ang2 potency over the current market leader faricimab, coupled with a smaller protein format, gives OLN324 the potential for best-in-class disease control. OLN324 is being tested at higher molar doses than faricimab for greater target coverage and the potential for extended treatment durability. These features give OLN324 the potential for a differentiated, first-line standard of care profile. "Both VEGF and Ang2 play important roles in the vascular pathologies that drive wAMD and DME. Dual targeting has the potential to improve anatomic outcomes and achieve more durable disease control compared to VEGF inhibition alone. Uptake of the first U.S. FDA-approved VEGF/Ang2 inhibitor, faricimab, underscores the interest from retinal specialists and patients for new medicines offering improved outcomes by targeting more than one driver of disease," said Charles C. Wykoff, MD, PhD, Chairman of Research, Retina Consultants of America, and member of Ollin's Scientific Advisory Board. "There remains meaningful room for further clinical improvement for patients. Ollin's Phase 1b study explores the potential for differentiation of OLN324 versus faricimab from the outset." Dr. Lei Qian, Chief R&D Officer of General Biomedicine from Innovent Biologics, stated: "We are excited about by the progress of OLN324 (IBI324), driven forward by our partner Ollin—especially the successful enrollment completion of the JADE Phase 1b trial, which represents a key milestone that validates both parties' strong collaboration. As a next-generation VEGF/Ang-2 bispecific antibody, OLN324 (IBI324) holds promise for better anatomic outcomes and longer durability than current standards like faricimab. We remain aligned with Ollin to speed OLN324's development and bring this much needed therapy to market globally." In a completed Phase 1 single and multiple dose escalation study, IBI324 (OLN324) demonstrated promising vision and anatomic improvements in DME patients along with a favorable safety profile. IBI324 (OLN324) was discovered by Innovent and is being developed in collaboration with Ollin. About Ollin Established in 2023, Ollin BiosciencesTM is a clinical-stage biopharmaceutical company dedicated to acquiring and developing best-in-disease therapies for vision-threatening diseases. With a differentiated pipeline, world-class team, and strong investor syndicate, Ollin is redefining what's possible in ophthalmology. For more information, please visit . About Innovent Innovent is a leading biopharmaceutical company founded in 2011 with the mission to empower patients worldwide with affordable, high-quality biopharmaceuticals. The company discovers, develops, manufactures and commercializes innovative medicines that target some of the most intractable diseases. Its pioneering therapies treat cancer, cardiovascular and metabolic, autoimmune and eye diseases. Innovent has launched 16 products in the market. It has 2 new drug applications under regulatory review, 4 assets in Phase 3 or pivotal clinical trials and 15 more molecules in early clinical stage. Innovent partners with over 30 global healthcare companies, including Eli Lilly, Sanofi, Incyte, LG Chem and MD Anderson Cancer Center. Guided by the motto, "Start with Integrity, Succeed through Action," Innovent maintains the highest standard of industry practices and works collaboratively to advance the biopharmaceutical industry so that first-rate pharmaceutical drugs can become widely accessible. For more information, visit , or follow Innovent on Facebook and LinkedIn. Statement: Innovent does not recommend the use of any unapproved drug (s)/indication (s). Forward-looking statement This news release may contain certain forward-looking statements that are, by their nature, subject to significant risks and uncertainties. The words "anticipate", "believe", "estimate", "expect", "intend" and similar expressions, as they relate to Innovent Biologics ("Innovent"), are intended to identify certain of such forward-looking statements. The Company does not intend to update these forward-looking statements regularly. These forward-looking statements are based on the existing beliefs, assumptions, expectations, estimates, projections and understandings of the management of the Company with respect to future events at the time these statements are made. These statements are not a guarantee of future developments and are subject to risks, uncertainties and other factors, some of which are beyond the Company's control and are difficult to predict. Consequently, actual results may differ materially from information contained in the forward-looking statements as a result of future changes or developments in our business, the Company's competitive environment and political, economic, legal and social conditions. The Company, the Directors and the employees of the Company assume (a) no obligation to correct or update the forward-looking statements contained in this site; and (b) no liability in the event that any of the forward-looking statements does not materialise or turn out to be incorrect. SOURCE Innovent Biologics WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

Phase 1

100 Deals associated with Faricimab

External Link

KEGG	Wiki	ATC	Drug Bank
D11516	Faricimab	-	DB15303

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Angioid Streaks	Japan	Chugai Pharmaceutical Co., Ltd.	19 May 2025
Retinal vein occlusion-related macular edema	Australia	Roche Products Pty Ltd.	08 Aug 2022
Age Related Macular Degeneration	Japan	Chugai Pharmaceutical Co., Ltd.	28 Mar 2022
Choroidal Neovascularization	Japan	Chugai Pharmaceutical Co., Ltd.	28 Mar 2022
Dystrophy, Macular	Japan	Chugai Pharmaceutical Co., Ltd.	28 Mar 2022
Diabetic macular oedema	United States	Genentech, Inc.	28 Jan 2022
Wet age-related macular degeneration	United States	Genentech, Inc.	28 Jan 2022

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Retinal Vein Occlusion	NDA/BLA	United States	Roche Holding AG	09 May 2023
Proliferative retinopathy with diabetes mellitus	Phase 3	United States	Genentech, Inc.	04 Aug 2025
Myopic choroidal neovascularization	Phase 3	China	F. Hoffmann-La Roche Ltd.	28 Feb 2024
Myopic choroidal neovascularization	Phase 3	China	Roche China Holding Ltd.	28 Feb 2024
Myopic choroidal neovascularization	Phase 3	Australia	Roche China Holding Ltd.	28 Feb 2024
Myopic choroidal neovascularization	Phase 3	Australia	F. Hoffmann-La Roche Ltd.	28 Feb 2024
Myopic choroidal neovascularization	Phase 3	France	F. Hoffmann-La Roche Ltd.	28 Feb 2024
Myopic choroidal neovascularization	Phase 3	France	Roche China Holding Ltd.	28 Feb 2024
Myopic choroidal neovascularization	Phase 3	Germany	F. Hoffmann-La Roche Ltd.	28 Feb 2024
Myopic choroidal neovascularization	Phase 3	Germany	Roche China Holding Ltd.	28 Feb 2024

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT04777201 (AVONELLE-X, NEWS \| GlobeNewswire) Manual	Phase 3	Age Related Macular Degeneration	1,029	Faricimab	lchueersuh(xjmxflgspt) = cmwedmxutt gyhuqimfod (cztinwghxk ) View more	Positive	04 Sep 2025
				Faricimab (prior aflibercept 2 mg)	lchueersuh(xjmxflgspt) = azxgkiiuis gyhuqimfod (cztinwghxk ) View more
CTR20222310 (SALWEEN, NEWS) Manual	Phase 3	Polypoidal choroidal vasculopathy	135	Faricimab	csocpplfsh(dqeqtsrmlo) = yluacaiymh rckrgxlzum (ilrridvozh ) View more	Positive	04 Sep 2025
EURETINA2025	Not Applicable	Diabetic macular oedema	134	Faricimab (nAMD)	ceqmwsuugj(irvsivnxey) = rhbvtmxfvx rvklfzsfwo (bqqytvmsmb, 87.5) View more	Positive	04 Sep 2025
				Faricimab (DMO)	ceqmwsuugj(irvsivnxey) = lpagzqitqr rvklfzsfwo (bqqytvmsmb, 128.0) View more
EURETINA2025	Not Applicable	Wet age-related macular degeneration	211	Faricimab	ipaqpdelfu(qfnvrcojaf) = zypbyvkufs usmsydpaxg (bmhoqshrrd ) View more	Positive	04 Sep 2025
NCT03622580 (YOSEMITE, EURETINA2025)	Phase 3	Diabetic macular oedema	246	Faricimab 6mg T&E	zxpohqgtdt(rwiyivhkyl): Difference = -1.1 (95.0% CI, -4.0 to 1.7) View more	Positive	04 Sep 2025
				aflibercept 8mg Q12W
EURETINA2025	Not Applicable	Retinal vein occlusion-related macular edema \| Diabetic macular oedema \| Neovascularization, Pathologic ... View more	30	Faricimab	aswacainbs(bpsfvsulqq) = Faricimab was discontinued in 4 patients due to lack of response and in 1 patient due to a myocardial infarction. tflvdwfrpp (jsnkugfcnr )	Positive	04 Sep 2025
EURETINA2025	Not Applicable	Polypoidal choroidal vasculopathy	111	Faricimab	lbcxgpvfqq(paefidsmjs): P-Value = 0.025 View more	Positive	04 Sep 2025
				Aflibercept
EURETINA2025	Not Applicable	Diabetic macular oedema	33	Faricimab 6mg	eaecncgteu(oufjyqnuoo) = ovkipqzeqh fihefpcftx (rdmazrwnow ) View more	Non-inferior	04 Sep 2025
				Aflibercept 2mg	eaecncgteu(oufjyqnuoo) = wdulhlljvt fihefpcftx (rdmazrwnow ) View more
EURETINA2025	Not Applicable	Polypoidal choroidal vasculopathy	28	Faricimab	euvovqbzyh(isxetolbfq) = zwnwbtnyij tsjkgxmctd (sqikvphxzx ) View more	Positive	04 Sep 2025
NCT04432831 (RONE-X, EURETINA2025)	Phase 3	Diabetic macular oedema	1,474	Faricimab 6.0 mg every 8 weeks (Q8W)	bcmwfenahg(cnmlojflgz) = after 4 years of treatment, faricimab led to DME absence (defined as CST <325 μm) in >90% of patients, regardless of original parent trial treatment assignment. ksrvkvxitk (bllyyfxszy ) View more	Positive	04 Sep 2025
				Faricimab 6.0 mg up to Q16W T&E

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis